Aldeyra Therapeutics, Inc.
ALDX
$2.19
$0.188.96%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 11.89M | 11.74M | 10.64M | 10.98M | 13.34M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 60.12M | 49.64M | 43.05M | 35.38M | 42.79M |
Operating Income | -60.12M | -49.64M | -43.05M | -35.38M | -42.79M |
Income Before Tax | -55.85M | -44.80M | -37.87M | -30.01M | -37.54M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -55.85 | -44.80 | -37.87 | -30.01 | -37.54 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -55.85M | -44.80M | -37.87M | -30.01M | -37.54M |
EBIT | -60.12M | -49.64M | -43.05M | -35.38M | -42.79M |
EBITDA | -59.87M | -49.39M | -42.80M | -35.13M | -42.53M |
EPS Basic | -0.94 | -0.75 | -0.64 | -0.51 | -0.64 |
Normalized Basic EPS | -0.59 | -0.47 | -0.40 | -0.32 | -0.40 |
EPS Diluted | -0.94 | -0.75 | -0.64 | -0.51 | -0.64 |
Normalized Diluted EPS | -0.59 | -0.47 | -0.40 | -0.32 | -0.40 |
Average Basic Shares Outstanding | 237.94M | 237.56M | 237.02M | 236.39M | 235.77M |
Average Diluted Shares Outstanding | 237.94M | 237.56M | 237.02M | 236.39M | 235.77M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |